Alpha 2.0
Login Register
» Authors » Lun-Xu Liu

Lun-Xu Liu

Explore the profile of Lun-Xu Liu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 60
Citations 895
Followers 0
Related Specialties
General Medicine
Oncology
Pulmonary Medicine
Top 10 Co-Authors
Guo-Wei Che
Qiang Pu
Yun Wang
Qing-Hua Zhou
Yi-Dan Lin
Ying-Li Kou
Jian-Dong Mei
Lin Ma
Zhu Wu
Yi-Long Wu
Published In
Sichuan Da Xue Xue Bao Yi Xue Ban
J Thorac Dis
Zhonghua Wai Ke Za Zhi
Zhonghua Zhong Liu Za Zhi
Chin Med J (Engl)
Affiliations
Soon will be listed here.
Recent Articles
1.
Baicalein relieves lung graft ischemia-reperfusion injury by reducing advanced glycation endproducts: From screens to mechanisms
Tian D, Zheng X, Hou S, Yu Z, Wu Y, Liu P, et al.
J Heart Lung Transplant . 2025 Feb; PMID: 39954833
Background: The lack of effective drugs for treating ischemia-reperfusion injury (IRI) in lung transplants (LTx) remains an issue. Traditional Chinese medicine (TCM) ingredients are promising but poorly studied in LTx....
2.
Real-World Survival Outcomes Based on Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Yang X, Yan H, Wang J, Chu X, Liu Z, Shen Y, et al.
JTO Clin Res Rep . 2022 Jan; 3(1):100257. PMID: 34977823
Introduction: The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD) remains unstandardized. We analyzed the survival outcomes of these patients based on mutation status and adjuvant chemotherapy treatment. Methods:...
3.
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Liu S, Bao H, Wang Q, Mao W, Chen Y, Tong X, et al.
Nat Commun . 2021 Nov; 12(1):6450. PMID: 34750392
The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced...
4.
Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis
Guo C, Mei J, Jia Y, Gan F, Tang Y, Liu C, et al.
Chin Med J (Engl) . 2021 Nov; 134(22):2700-2709. PMID: 34732663
Background: There is limited information about thymosin α1 (Tα1) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, in patients with non-small cell lung cancer (NSCLC). This...
5.
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer
Ni J, Huang M, Zhang L, Wu N, Bai C, Chen L, et al.
Thorac Cancer . 2021 Mar; 12(9):1469-1488. PMID: 33787090
Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as...
6.
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Zhong W, Wang Q, Mao W, Xu S, Wu L, Wei Y, et al.
J Clin Oncol . 2020 Dec; 39(7):713-722. PMID: 33332190
Purpose: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth...
7.
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Zeng J, Mao W, Chen Q, Luo T, Wu Y, Zhou Q, et al.
Lung Cancer . 2020 Nov; 150:164-171. PMID: 33186858
Objectives: Health-related quality of life (HRQoL) data complement conventional clinical endpoints when comparing adjuvant gefitinib with chemotherapy in patients with early-stage non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor...
8.
Albumin-to-alkaline phosphatase ratio as a novel prognostic indicator for patients undergoing minimally invasive lung cancer surgery: Propensity score matching analysis using a prospective database
Li S, Lv W, Du H, Li Y, Zhang W, Che G, et al.
Int J Surg . 2019 Jul; 69:32-42. PMID: 31319230
Objectives: To evaluate prognostic significance of albumin-to-alkaline phosphatase ratio (AAPR) for patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for non-small-cell lung cancer (NSCLC) by a propensity score-matching (PSM) analysis. Methods:...
9.
Fat-free mass index is superior to body mass index as a novel risk factor for prolonged air leak complicating video-assisted thoracoscopic surgery lobectomy for non-small-cell lung cancer
Li S, Wang Z, Zhang W, Li Y, Cheng S, Che G, et al.
J Thorac Dis . 2019 Jul; 11(5):2006-2023. PMID: 31285894
Background: To evaluate whether fat-free mass index (FFMI) could be predictive of prolonged air leak (PAL) complicating video-assisted thoracoscopic (VATS) lobectomy for non-small-cell lung cancer (NSCLC). Methods: A retrospective study...
10.
Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study
Chen B, Wang X, Yu X, Xia W, Zhao H, Li X, et al.
Thorac Cancer . 2019 Jan; 10(3):533-542. PMID: 30666800
Background: Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node...